J. Curtis
I. McInnes
P. Rahman
D. D. Gladman
F. Yang
S. Peterson
A. Kollmeier
N. Shiff
C. Han
M. Shawi
W. Tillett
P. J. Mease
University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom
Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St John’s, Canada
Toronto Western Hospital, Centre for Prognosis in the Rheumatic Diseases, Toronto, Canada
, Janssen Global Services, LLC, Horsham, PA, United States of America
Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America
Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America
University of Saskatchewan, Community Health and Epidemiology, Saskatoon, Canada
Janssen Research & Development, Raritan, United States of America
Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America
Royal National Hospital for Rheumatic Diseases, Department of Pharmacy & Pharmacology Centre for Therapeutic Innovation, Bath, United Kingdom
Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Rheumatology Research, Seattle, United States of America
United States
United Kingdom
Canada
N/A
Autoimmune (AI)
Musculoskeletal
Dermatology
Central Nervous System (CNS)
Psoriatic arthritis
Depression
Inflammatory Arthritis
Anxiety
N/A
guselkumab (IV)
N/A
Placebo Control
III
N/A
Abbvie
N/A